Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Cullinan Therapeutics (NASDAQ:CGEM) and maintained a price target of $36.
September 18, 2024 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating for Cullinan Therapeutics and maintained a price target of $36, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $36 price target by a reputable analyst suggests positive sentiment and potential upside for Cullinan Therapeutics. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100